Abstract
The effects of 5-HT3 receptor antagonists (ondansetron 0.1 mg kg−1 SC 30 min; bemesetron 0.03 mg kg−1 SC 45 min) on nicotine-induced increases in locomotor activity were measured in male Sprague-Dawley rats. Intermittent daily injections of nicotine (0.3–1.2 mg kg−1 SC 30 min) resulted in increased locomotor activity as measured by photocell counts. The effect of nicotine was not affected by administration of the 5-HT3 receptor antagonists at doses that are reported to block nicotine- and morphine-induced place-preference conditioning. Neither of the 5-HT3 receptor antagonists tested affected activity counts in vehicle treated animals. Nicotine-induced hyperactivity was blocked by the dopamine antagonist haloperidol (0.03 mg kg−1 SC 2 h) and by the nicotinic antagonist mecamylamine (1 mg kg−1 SC 1 min). The effects of a range of doses (0–1 mg kg−1) of the 5-HT3 receptor antagonists ondansetron, bemesetron, granisetron and tropisetron on hyperactivity induced by 0.6 mg kg−1 nicotine were then assessed. Only tropisetron at 1 mg kg−1 attenuated nicotine-induced hyperactivity. To demonstrate the efficacy of the present range of doses of the 5-HT3 receptor antagonists in this study, conditioned taste aversion experiments were conducted. Ondansetron (0.1 mg kg−1) failed to attenuate a conditioned taste aversion to saccharin induced by nicotine (0.6 mg kg−1), but did induce a reduction in saccharin preference in choice tests following three saccharin-ondansetron pairings. This conditioned reduction in saccharin preference was replicated with this dose of ondansetron and extended to bemesetron (0.03 mg kg−1) and granisetron (0.1 mg kg−1) in a subsequent experiment. Nicotine-induced hyperactivity and place-preference conditioning are associated with dopamine release in the nucleus accumbens. The present data appear to be inconsistent with the proposal that 5-HT3 receptor antagonists decrease the behavioural effects of increased dopamine release in the nucleus accumbens.
Similar content being viewed by others
References
Blandina P, Goldfarb J, Green JP (1988) Activation of a 5-HT3 receptor releases dopamine from rat striatal slice. Eur J Pharmacol 155:349–350
Carboni E, Acquas E, Leone P, Perezzani L, Di Chiara G (1988) 5-HT3 receptor antagonists block morphine- and nicotine-induced place-preference conditioning. Eur J Pharmacol 151:159–160
Carboni E, Acquas E, Frau R, Di Chiara G (1989a) Differential inhibitory effects of a 5-HT3 antagonist on drug-induced stimulation of dopamine release. Eur J Pharmacol 164:515–519
Carboni E, Acquas E, Leone P, Di Chiara G (1989b) 5-HT3 receptor antagonists block morphine- and nicotine- but not amphetamine-induced reward. Psychopharmacology 97:175–178
Carr GD, White NM (1983) Conditioned place-preference from intra-accumbens but not intra-caudate amphetamine injections. Life Sci 33:2551–2554
Clarke PBS (1990a) Dopaminergic mechanisms in the locomotor stimulant effects of nicotine. Biochem Pharmacol 40:1427–1432
Clarke PBS (1990b) Mesolimbic dopamine activition — the key to nicotine reinforcement? Ciba Foundation Symposium 152:153–168
Clarke PBS, Kumar R (1983a) Characterization of the locomotor stimulant action of nicotine in tolerant rats. Br J Pharmacol 80:587–594
Clarke PBS, Kumar R (1983b) The effects of nicotine on locomotor activity in non-tolerant and tolerant rats. Br J Pharmacol 78:329–337
Clarke PBS, Fu DS, Jakubovic A, Fibiger HC (1988) Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J Pharmacol Exp Ther 246:701–708
Corrigall WA, Coen KM (1994) Nicotine self-administration and locomotor activity are not modified by the 5-HT3 antagonists ICS 205-930 and MLD 72222. Pharmacol Biochem Behav 49:67–71
Costall B, Domeney AM, Naylor RJ, Tyers MB (1987a) Antipsychotic potential of GR38032F, a selective antagonist of 5-HT3 receptors in the central nervous system. Br J Pharmacol 90:89P
Costall B, Domeney AM, Naylor RJ, Tyers MB (1987b) Effects of the 5-HT3 receptor antagonist GR38032F on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881–894
Costall B, Domeney AM, Naylor RJ, Tyers MB (1988) Inhibition by 5-HT3 antagonists of hyperactivity caused by dopamine infusion into the rat nucleus accumbens. Br J Pharmacol 93:194P
Derkach V, Suprenant A, North RA (1989) 5-HT3 receptors are membrane ion channels. Nature (London) 339:706–708
DiChiara G, Imperato A (1988) Drugs of abuse preferentially increase synaptic dopamine concentratins in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85:5274–5278
Domeney AM, Costall B, Gerrard PA, Jones DNC, Naylor RJ, Tyers MB (1991) The effect of ondansetron on cognitive performance in the marmoset. Pharmacol Biochem Behav 38:169–175
Dunn RW, Carlezon Jr WA, Corbett R (1991) Preclinical anxiolytic versus antipsychotic profiles of the 5-HT3 antagonists ondansetron, zacopride, 3-tropanyl-1H-indole-3-carboxylic acid ester, and 1H, 3, 5H-tropan-3-yl-3,5-dichlorobenzoate. Drug Dev Res 23:289–300
Fung YK (1990) The importance of nucleus accumbens in nicotine-induced locomotor activity. J Pharm Pharmacol 42:595–596
Geissler MA, Torrente JR, Eison AS, Gylys JA, Wright RN, Iben LG, Davis HH, Yocca FD (1993) Effects of BMY 33462, a selective and potent serotonin type-3 receptor antagonist, on mesolimbic dopamine-mediated behaviour. Drug Dev Res 29:18–24
Gilbert DB, Millar J, Greenwood S, Cooper SJ (1992) Failure to antagonized-amphetamine's effects with ondansetron, a selective 5-HT3 antagonist. Proc 7th Int Catecholamine Symposium, Amsterdam, Netherlands, June 22–26
Greenshaw AJ (1993a) Behavioural pharmacology of 5-HT3 receptor antagonists: a critical update on therapeutic potential. Trends Pharmacol Sci 14:265–270
Greenshaw AJ (1993b) Differential effects of ondansetron, haloperidol and clozapine on electrical self-stimulation of the ventral tegmental area. Behav Pharmacol 4:479–485
Greenshaw AJ, Nazarali AJ, Rao TS, Baker GB (1988) Chronic tranylcypromine treatment induces functional α2 noradrenaline receptor down-regulation in rats. Eur J Pharmacol 154:67–72
Hagan RM, Butler A, Hill JM, Jordan CC, Ireland SJ, Tyers MB (1987) Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain. Eur J Pharmacol 138:303–305
Herberg LJ, De Belleroche JS, Rose IC, MOntgomery AMJ (1992) Effect of the 5-HT3 receptor antagonist ondansetron on hypothalamic self-stimulation in rats and its interaction with the CCK analogue caerulein. Neurosci Lett 140:16–18
Higgins GA, Joharchi N, Nguyen P, Sellers EM (1992) Effect of the 5-HT3 receptor antagonists, MDL72222 and ondansetron on morphine place conditioning. Psychopharmacology 106:315–320
Imperato A, Angelucci L (1989) 5-HT3 receptors control dopamine release in nucleus accumbens of freely moving rats. Neurosci Lett 101:214–217
Imperato A, Mulas A, Di Chiara G (1986) Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132:337–338
Jones BJ, Costall B, Domeney AM, Kelly ME, Naylor RJ, Oakley NR, Tyers MB (1988) The potential anxiolytic activity of GR38032F, a 5-HT3 receptor antagonist. Br J Pharmacol 93:985–993
Kilpatrick GJ, Jones BJ, Tyers MB (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature (Lond) 330:746–748
Kilpatrick GJ, Jones BJ, Tyers MB (1988) The distribution of specific binding of the 5-HT3 receptor ligand [3H-] Gr 65630 in rat brain using quantitative autoradiography. Neurosci Lett 94:156–160
Kilpatrick GJ, Jones BJ, Tyers MB (1989) Binding of the 5-HT3 ligand [3H-] GR65630 to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 159:157–164
Lane JD, Pickering CL, Hooper ML, Fagan K, Tyers MB, Emmett-Oglesby MW (1992) Failure of ondansetron to block the discriminative or reinforcing stimulus effects of cocaine in the rat. Drug Alcohol Depend 30:151–162
Leonard BE (1992) Sub-types of serotonin receptors: biochemical changes and pharmacological consequences. Int Clin Psychopharmacol 7:13–21
Mele PC, McDonough JR, McLean DB, O'Halloran KP (1992) Cisplatin-induced conditioned taste aversion: attenuation by dexamethasone but not zacopride or GR38032F. Eur J Pharmacol 218:229–236
Middlemiss DN, Tricklebank MD (1992) Centrally active 5-HT receptor agonists and antagonists. Neurosci Biobehav Rev 16:75–82
Moser PC (1992) The effect of 5-HT3 receptor antagonists on the discriminative stimulus effects of amphetamine. Eur J Pharmacol 212:271–274
Museo E, Wise RA (1990a) Locomotion induced by ventral tegmental microinjections of a nicotinic agonist. Pharmacol Biochem Behav 35:735–737
Museo E, Wise RA (1990b) Microinjections of a nicotinic agonist into dopamine terminal fields: effects on locomotion. Pharmacol Biochem Behav 37:113–116
O'Neill MF, Dourish CT, Iversen SD (1991) Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats. Psychopharmacol 104:343–350
Pei Q, Zetterström, Leslie RA, Grahame-Smith DG (1993) 5-HT3 receptor antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. Eur J Pharmacol 230:63–68
Shen Y, Monsma Jr FJ, Metcalf MA, Jose MA, Hamblin MW, Sibley DR (1993) Molecular cloning and expression of a 5-hydroxytryptamine7, receptor subtype. J Biol Chem 268:18200–18204
Spanagel R, Herz A, Bals-Kubik R, Shippenberg TS (1991) β-Endorphin-induced locomotor stimulation and reinforcement are associated with an increase in dopamine release in the nucleus accumbens. Psychopharmacology 1994 104:51–56
Spyraki C, Fibiger HC, Phillips AG (1982) Dopaminergic substrates of amphetamine-induced place preference conditioning. Brain Res 253:185–190
Tricklebank MD (1989) Interactions between dopamine and 5-HT3 receptors suggest new treatments for psychosis and drug addiction. Trends Pharmacol Sci 10:127–128
Tyers MB (1991) 5-HT3 receptors and the therapeutic potential of 5-HT3 antagonists. Therapie 46:431–435
Winer BJ (1971) Statistical principles in experimental design. McGraw Hill, New York
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arnold, B., Allison, K., Ivanová, S. et al. 5HT3 receptor antagonists do not block nicotine induced hyperactivity in rats. Psychopharmacology 119, 213–221 (1995). https://doi.org/10.1007/BF02246163
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02246163